Future clinical prospects of C-peptide testing in the early diagnosis of gestational diabetes  

作　　者：Charalampos Milionis Ioannis Ilias Anastasia Lekkou Evangelia Venaki Eftychia Koukkou 

机构地区：[1]Department of Endocrinology,Diabetes,and Metabolism,‘Elena Venizelou’General Hospital,Athens 11521,Greece

出　　处：《World Journal of Experimental Medicine》2024年第1期13-21,共9页世界实验医学杂志

摘　　要：Gestational diabetes is typically diagnosed in the late second or third trimester of pregnancy.It is one of the most common metabolic disorders among expectant mothers,with potential serious short-and long-term complications for both maternal and offspring health.C-peptide is secreted from pancreatic beta-cells into circulation in equimolar amounts with insulin.It is a useful biomarker to estimate the beta-cell function because it undergoes negligible hepatic clearance and consequently it has a longer half-life compared to insulin.Pregnancy induces increased insulin resistance due to physiological changes in hormonal and metabolic homeostasis.Inadequate compensation by islet beta-cells results in hyperglycemia.The standard oral glucose tolerance test at 24-28 wk of gestation sets the diagnosis.Accumulated evidence from prospective studies indicates a link between early pregnancy C-peptide levels and the risk of subsequent gestational diabetes.Elevated C-peptide levels and surrogate glycemic indices at the beginning of pregnancy could prompt appropriate strategies for secondary prevention.

关 键 词：C-PEPTIDE Gestational diabetes Secondary prevention PREGNANCY Clinical laboratory techniques 

分 类 号：R58[医药卫生—内分泌]